Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
abemaciclib save search
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
Published: 2023-11-28 (Crawled : 13:00) - globenewswire.com
EFTR | $1.82 -6.19% -6.59% 110K
|
|
| O: 8.71%
H: 0.0%
C: -8.51%
fda breast cancer treatment designation
Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer
Published: 2023-10-20 (Crawled : 12:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.52%
H: 0.0%
C: 0.0%
verzenio breast cancer impact
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
Published: 2023-09-19 (Crawled : 13:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.06%
H: 1.19%
C: 0.58%
bbi-355 verzenio tumors collaboration trial agreement
U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
Published: 2023-03-03 (Crawled : 21:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
| Email alert
Add to watchlist
verzenio fda risk breast cancer
Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology
Published: 2021-10-28 (Crawled : 20:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.17%
H: 1.06%
C: 0.39%
ema phase 3 trial
Quest Diagnostics to Introduce Ki-67 IHC MIB-1 pharmDx, the First Companion Diagnostic for Eli Lilly and Company's Verzenio® (abemaciclib), a CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
DGX | News | $137.55 0.62% 0.0% 1.6M
|
Health Services
|
| O: -0.18%
H: 1.13%
C: 1.04%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.14%
H: 1.98%
C: 0.43%
A | $137.49 -1.23% -0.36% 1.6M
|
Health Technology
|
| O: 0.23%
H: 1.17%
C: 0.75%
ema risk cancer breast cancer diagnostics her2+ diagnostic her2- her2
Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology
Published: 2021-10-14 (Crawled : 19:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.24%
H: 0.6%
C: -0.14%
phase 3 trial
FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Published: 2021-10-13 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.55%
H: 1.64%
C: 1.01%
fda risk cancer breast cancer fda approval her2+ her2- her2
New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary
Published: 2021-09-27 (Crawled : 13:15) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.